Novartis stock hits 52-week high but downgraded to Hold after Q4 sales drop in heart failure drug Entresto.

Novartis AG's stock reached a 52-week high of $170.46 on February 27, 2025, but then faced a correction due to a 33.2% decline in Q4 sales of its heart failure drug Entresto, which fell to $1.25 billion. The stock is now trading at a forward non-GAAP P/E ratio of 17x, 20.1% above its five-year average and aligned with the sector average. Due to these factors and expectations for the upcoming Q1 report, the analyst downgraded Novartis' rating from Buy to Hold, signaling caution for investors despite recent highs.